Displaying 1701 - 1720 of 2062
FTC Puts Conditions on Keystone's $245 Million Purchase of Compagnie de Saint-Gobain's Advanced Ceramics Business
Bisaro, Paul
FTC Testifies on Antitrust Enforcement in the Health Care Industry
FTC Puts Conditions on Simon Property Group's Acquisition of Prime Outlets
Promedica Health System, Inc.
Dun & Bradstreet Settles FTC Charges that 2009 Acquisition was Anticompetitive
Fidelity National Financial Settles FTC Charges that its Acquisition of LandAmerica Subsidiaries Reduced Competition in Title Information Markets
FTC Approves Final Settlement Regarding Agilent Technologies' Proposed Acquisition of Varian
FTC Contributes Report to White House Council on Women and Girls
FTC Order Preserves Competition Threatened by Agilent's Acquisition of Varian
FTC Order Preserves Competition That Would Have Been Eliminated by SCI's Acquisition of Keystone North America Inc.
Administrative Law Judge Rules That Polypore International's 2008 Acquisition of Rival Battery Separator Manufacturer Violated Antitrust Law
FTC Approves Final Consent Order in Case of Pfizer Inc. and Wyeth
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
FTC Order Preserves Competition Lost Through SCI's Acquisition of Palm Mortuary
FTC Order Sets Conditions for Panasonic's Acquisition of Sanyo
Displaying 1701 - 1720 of 2062